Cargando…

Macrophage DCLK1 promotes obesity-induced cardiomyopathy via activating RIP2/TAK1 signaling pathway

Obesity increases the risk for cardiovascular diseases and induces cardiomyopathy. Chronic inflammation plays a significant role in obesity-induced cardiomyopathy and may provide new therapeutic targets for this disease. Doublecortin-like kinase 1 (DCLK1) is an important target for cancer therapy an...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Bin, Zhao, Yunjie, Luo, Wu, Zhu, Weiwei, Jin, Leiming, Wang, Minxiu, Ye, Lin, Wang, Yi, Liang, Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345119/
https://www.ncbi.nlm.nih.gov/pubmed/37443105
http://dx.doi.org/10.1038/s41419-023-05960-4
_version_ 1785073014811918336
author Yang, Bin
Zhao, Yunjie
Luo, Wu
Zhu, Weiwei
Jin, Leiming
Wang, Minxiu
Ye, Lin
Wang, Yi
Liang, Guang
author_facet Yang, Bin
Zhao, Yunjie
Luo, Wu
Zhu, Weiwei
Jin, Leiming
Wang, Minxiu
Ye, Lin
Wang, Yi
Liang, Guang
author_sort Yang, Bin
collection PubMed
description Obesity increases the risk for cardiovascular diseases and induces cardiomyopathy. Chronic inflammation plays a significant role in obesity-induced cardiomyopathy and may provide new therapeutic targets for this disease. Doublecortin-like kinase 1 (DCLK1) is an important target for cancer therapy and the role of DCLK1 in obesity and cardiovascular diseases is unclear. Herein, we showed that DCLK1 was overexpressed in the cardiac tissue of obese mice and investigated the role of DCLK1 in obesity-induced cardiomyopathy. We generated DCLK1-deleted mice and showed that macrophage-specific DCLK1 knockout, rather than cardiomyocyte-specific DCLK1 knockout, prevented high-fat diet (HFD)-induced heart dysfunction, cardiac hypertrophy, and fibrosis. RNA sequencing analysis showed that DCLK1 deficiency exerted cardioprotective effects by suppressing RIP2/TAK1 activation and inflammatory responses in macrophages. Upon HFD/palmitate (PA) challenge, macrophage DCLK1 mediates RIP2/TAK1 phosphorylation and subsequent inflammatory cytokine release, which further promotes hypertrophy in cardiomyocytes and fibrogenesis in fibroblasts. Finally, a pharmacological inhibitor of DCLK1 significantly protects hearts in HFD-fed mice. Our study demonstrates a novel role and a pro-inflammatory mechanism of macrophage DCLK1 in obesity-induced cardiomyopathy and identifies DCLK1 as a new therapeutic target for the treatment of this disease. [Figure: see text]
format Online
Article
Text
id pubmed-10345119
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-103451192023-07-15 Macrophage DCLK1 promotes obesity-induced cardiomyopathy via activating RIP2/TAK1 signaling pathway Yang, Bin Zhao, Yunjie Luo, Wu Zhu, Weiwei Jin, Leiming Wang, Minxiu Ye, Lin Wang, Yi Liang, Guang Cell Death Dis Article Obesity increases the risk for cardiovascular diseases and induces cardiomyopathy. Chronic inflammation plays a significant role in obesity-induced cardiomyopathy and may provide new therapeutic targets for this disease. Doublecortin-like kinase 1 (DCLK1) is an important target for cancer therapy and the role of DCLK1 in obesity and cardiovascular diseases is unclear. Herein, we showed that DCLK1 was overexpressed in the cardiac tissue of obese mice and investigated the role of DCLK1 in obesity-induced cardiomyopathy. We generated DCLK1-deleted mice and showed that macrophage-specific DCLK1 knockout, rather than cardiomyocyte-specific DCLK1 knockout, prevented high-fat diet (HFD)-induced heart dysfunction, cardiac hypertrophy, and fibrosis. RNA sequencing analysis showed that DCLK1 deficiency exerted cardioprotective effects by suppressing RIP2/TAK1 activation and inflammatory responses in macrophages. Upon HFD/palmitate (PA) challenge, macrophage DCLK1 mediates RIP2/TAK1 phosphorylation and subsequent inflammatory cytokine release, which further promotes hypertrophy in cardiomyocytes and fibrogenesis in fibroblasts. Finally, a pharmacological inhibitor of DCLK1 significantly protects hearts in HFD-fed mice. Our study demonstrates a novel role and a pro-inflammatory mechanism of macrophage DCLK1 in obesity-induced cardiomyopathy and identifies DCLK1 as a new therapeutic target for the treatment of this disease. [Figure: see text] Nature Publishing Group UK 2023-07-13 /pmc/articles/PMC10345119/ /pubmed/37443105 http://dx.doi.org/10.1038/s41419-023-05960-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Yang, Bin
Zhao, Yunjie
Luo, Wu
Zhu, Weiwei
Jin, Leiming
Wang, Minxiu
Ye, Lin
Wang, Yi
Liang, Guang
Macrophage DCLK1 promotes obesity-induced cardiomyopathy via activating RIP2/TAK1 signaling pathway
title Macrophage DCLK1 promotes obesity-induced cardiomyopathy via activating RIP2/TAK1 signaling pathway
title_full Macrophage DCLK1 promotes obesity-induced cardiomyopathy via activating RIP2/TAK1 signaling pathway
title_fullStr Macrophage DCLK1 promotes obesity-induced cardiomyopathy via activating RIP2/TAK1 signaling pathway
title_full_unstemmed Macrophage DCLK1 promotes obesity-induced cardiomyopathy via activating RIP2/TAK1 signaling pathway
title_short Macrophage DCLK1 promotes obesity-induced cardiomyopathy via activating RIP2/TAK1 signaling pathway
title_sort macrophage dclk1 promotes obesity-induced cardiomyopathy via activating rip2/tak1 signaling pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345119/
https://www.ncbi.nlm.nih.gov/pubmed/37443105
http://dx.doi.org/10.1038/s41419-023-05960-4
work_keys_str_mv AT yangbin macrophagedclk1promotesobesityinducedcardiomyopathyviaactivatingrip2tak1signalingpathway
AT zhaoyunjie macrophagedclk1promotesobesityinducedcardiomyopathyviaactivatingrip2tak1signalingpathway
AT luowu macrophagedclk1promotesobesityinducedcardiomyopathyviaactivatingrip2tak1signalingpathway
AT zhuweiwei macrophagedclk1promotesobesityinducedcardiomyopathyviaactivatingrip2tak1signalingpathway
AT jinleiming macrophagedclk1promotesobesityinducedcardiomyopathyviaactivatingrip2tak1signalingpathway
AT wangminxiu macrophagedclk1promotesobesityinducedcardiomyopathyviaactivatingrip2tak1signalingpathway
AT yelin macrophagedclk1promotesobesityinducedcardiomyopathyviaactivatingrip2tak1signalingpathway
AT wangyi macrophagedclk1promotesobesityinducedcardiomyopathyviaactivatingrip2tak1signalingpathway
AT liangguang macrophagedclk1promotesobesityinducedcardiomyopathyviaactivatingrip2tak1signalingpathway